E. Lynne Kelley, MD, is the CEO and Co-Founder, Xenthera/Signalexis, a clinical stage oncology drug development company, and an experienced medical professional providing both short and long term strategic and operational assistance across the spectrum of pharmaceutical, VC, biotech startups and device companies for medical affairs, clinical operations, pharmacovigilance, and regulatory submissions. Therapeutic areas include oncology, precision medicine and gene therapy, rare diseases, diabetes, orthopedics, cardiovascular disease, and drug delivery. Her current assignments are with clinical stage companies in modified T-cell therapies and regenerative medicine applications for oncology and non-oncology indications.